Assembly Biosciences, Inc. (ASMB)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
ASMB Insider Trading Activity
ASMB Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $20,778,066 | 8 | 33 |
Sells | $139,156 | 16 | 67 |
Related Transactions
| GILEAD SCIENCES, INC. | 10 percent owner | 2 | $20.1M | 0 | $0 | $20.1M |
| Schornstein Alexander | 10 percent owner | 5 | $629,425 | 0 | $0 | $629,425 |
| Houghton Michael | director | 1 | $49,998 | 0 | $0 | $49,998 |
| Bjorkquist Jeanette M | Principal Accounting Officer | 0 | $0 | 2 | $1,849 | $-1,849 |
| White Nicole S | Chief Manufacturing Officer | 0 | $0 | 6 | $35,240 | $-35,240 |
| McHutchison John G | director | 0 | $0 | 2 | $47,380 | $-47,380 |
| Okazaki Jason A | CEO and President | 0 | $0 | 6 | $54,688 | $-54,688 |
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Insider Activity of Assembly Biosciences, Inc.
Over the last 12 months, insiders at Assembly Biosciences, Inc. have bought $20.78M and sold $139,156 worth of Assembly Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Assembly Biosciences, Inc. have bought $10.79M and sold $159,949 worth of stock each year.
Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $20.1M. Schornstein Alexander (10 percent owner) — $629,425. Houghton Michael (director) — $49,998.
The last purchase of 3,202 shares for transaction amount of $49,998 was made by Houghton Michael (director) on 2024‑12‑30.
List of Insider Buy and Sell Transactions, Assembly Biosciences, Inc.
| 2024-12-30 | Houghton Michael | director | 3,202 0.0519% | $15.61 | $49,998 | -15.53% | ||
| 2024-12-19 | GILEAD SCIENCES, INC. | 10 percent owner | 940,499 20.3736% | $21.37 | $20.1M | -12.49% | ||
| 2024-11-25 | Schornstein Alexander | 10 percent owner | 7,976 0.126% | $14.91 | $118,890 | -2.57% | ||
| 2024-11-22 | Schornstein Alexander | 10 percent owner | 17,024 0.2729% | $14.87 | $253,104 | -3.96% | ||
| 2024-11-18 | Sale | White Nicole S | Chief Manufacturing Officer | 40 0.0006% | $16.29 | $652 | -8.49% | |
| 2024-10-08 | Schornstein Alexander | 10 percent owner | 10,000 0.1478% | $14.58 | $145,800 | +5.41% | ||
| 2024-10-03 | Sale | Okazaki Jason A | CEO and President | 197 0.003% | $14.81 | $2,918 | +2.89% | |
| 2024-10-03 | Sale | White Nicole S | Chief Manufacturing Officer | 157 0.0024% | $14.81 | $2,325 | +2.89% | |
| 2024-08-02 | Sale | Okazaki Jason A | CEO and President | 981 0.0158% | $14.23 | $13,962 | +6.37% | |
| 2024-08-02 | Sale | White Nicole S | Chief Manufacturing Officer | 785 0.0127% | $14.23 | $11,173 | +6.37% | |
| 2024-07-05 | Schornstein Alexander | 10 percent owner | 4,438 0.063% | $12.52 | $55,564 | +13.85% | ||
| 2024-07-03 | Schornstein Alexander | 10 percent owner | 4,562 0.0636% | $12.29 | $56,067 | +23.79% | ||
| 2024-06-17 | GILEAD SCIENCES, INC. | 10 percent owner | 179,500 0.0002% | $0.00 | $180 | -0.92% | ||
| 2024-05-23 | Sale | McHutchison John G | director | 2,117 0.0389% | $14.93 | $31,615 | +2.17% | |
| 2024-05-23 | Sale | Okazaki Jason A | CEO and President | 549 0.0101% | $14.93 | $8,199 | +2.17% | |
| 2024-05-23 | Sale | White Nicole S | Chief Manufacturing Officer | 172 0.0032% | $14.93 | $2,569 | +2.17% | |
| 2024-05-23 | Sale | Bjorkquist Jeanette M | Principal Accounting Officer | 24 0.0004% | $14.93 | $358 | +2.17% | |
| 2024-04-30 | Sale | Okazaki Jason A | CEO and President | 1,569 0.0292% | $12.71 | $19,937 | +20.09% | |
| 2024-04-30 | Sale | White Nicole S | Chief Manufacturing Officer | 1,255 0.0233% | $12.71 | $15,947 | +20.09% | |
| 2024-04-01 | Sale | McHutchison John G | director | 1,206 0.0223% | $13.07 | $15,765 | +15.43% |
Insider Historical Profitability
| GILEAD SCIENCES, INC. | 10 percent owner | 2209471 34.7604% | $23.99M | 2 | 0 | |
| Schornstein Alexander | 10 percent owner | 728113 11.455% | $7.91M | 9 | 0 | +64% |
| McHutchison John G | director | 19104 0.3006% | $207,469.44 | 0 | 8 | |
| Okazaki Jason A | CEO and President | 14904 0.2345% | $161,857.44 | 0 | 13 | |
| White Nicole S | Chief Manufacturing Officer | 11871 0.1868% | $128,919.06 | 0 | 8 | |
| Houghton Michael | director | 3202 0.0504% | $34,773.72 | 1 | 0 | |
| Bjorkquist Jeanette M | Principal Accounting Officer | 3142 0.0494% | $34,122.12 | 0 | 5 | |
| Small Derek A | CEO and President | 669291 10.5296% | $7.27M | 3 | 0 | <0.0001% |
| Lopatin Uri A | Chief Med. Off., VP Res. Dev. | 613611 9.6536% | $6.66M | 0 | 2 | |
| Delaney William E IV | Chief Scientific Officer | 150853 2.3733% | $1.64M | 0 | 8 | |
| Colonno Richard James | EVP & CSO, Virology Ops | 137009 2.1555% | $1.49M | 0 | 2 | |
| Samar Michael P. | Chief Financial Officer | 77228 1.215% | $838,696.08 | 0 | 2 | |
| ELLISON RUSSELL H | Chief Executive Officer | 58000 0.9125% | $629,880.00 | 6 | 0 | +59.75% |
| BARRETT DAVID JONATHAN | Chief Financial Officer | 46980 0.7391% | $510,202.80 | 3 | 0 | +86.04% |
| Stamm Luisa M | Chief Medical Officer | 40315 0.6343% | $437,820.90 | 0 | 2 | |
| Papkoff Jacqueline Sybil | SVP-CSO Microbiome | 37364 0.5878% | $405,773.04 | 0 | 3 | |
| RINGO WILLIAM R | director | 19465 0.3062% | $211,389.90 | 0 | 11 |
Historical Insider Profitability vs. Competitors
$2,600,095 | 110 | 13.50% | $70.91M | |
$2,942,496 | 100 | 17.32% | $66.91M | |
$4,898,715 | 46 | 40.74% | $73.28M | |
$329,102,560 | 42 | 30.96% | $73.82M | |
$542,300 | 40 | -14.44% | $67.8M | |
$22,110,933 | 34 | 30.18% | $67.48M | |
$144,247,213 | 29 | 10.15% | $64.24M | |
Assembly Biosciences, Inc. (ASMB) | $1,239,833 | 16 | 53.23% | $69.03M |
$277,862 | 15 | 59.79% | $69.24M | |
$14,562,799 | 14 | -4.77% | $71.91M | |
$17,567,343 | 12 | 34.87% | $66.01M | |
$91,549,696 | 8 | -6.55% | $70.56M | |
$32,684,649 | 8 | -15.84% | $64.71M | |
$106,599,960 | 6 | -7.63% | $65.44M | |
$141,999,928 | 6 | -34.00% | $71.32M | |
$26,254,149 | 5 | 49.97% | $69.95M | |
$20,729,984 | 5 | 51.71% | $66.8M | |
$105,079 | 4 | -41.57% | $70.25M | |
$4,030 | 1 | 9.14% | $68.86M |
ASMB Institutional Investors: Active Positions
| Increased Positions | 21 | +67.74% | 2M | +240.31% |
| Decreased Positions | 12 | -38.71% | 309,155 | -30.1% |
| New Positions | 10 | New | 2M | New |
| Sold Out Positions | 5 | Sold Out | 120,593 | Sold Out |
| Total Postitions | 40 | +29.03% | 3M | +210.2% |
ASMB Ownership Change vs Market
Institutional Investor Ownership
| Gilead Sciences, Inc. | $28,458.00 | 36.83% | 2.21M | +2M | New | 2024-12-31 |
| Vanguard Group Inc | $2,582.00 | 3.34% | 200,458 | 0 | 0% | 2024-12-31 |
| Armistice Capital, Llc | $2,165.00 | 2.8% | 168,074 | -185,926 | -52.52% | 2024-12-31 |
| Renaissance Technologies Llc | $1,220.00 | 1.58% | 94,711 | +29,087 | +44.32% | 2024-12-31 |
| Blackrock, Inc. | $1,050.00 | 1.36% | 81,529 | +4,421 | +5.73% | 2024-12-31 |
| Peapod Lane Capital Llc | $811.00 | 1.05% | 62,970 | +62,970 | New | 2024-12-31 |
| B Group, Inc. | $652.00 | 0.84% | 50,651 | +50,651 | New | 2024-12-31 |
| Geode Capital Management, Llc | $601.00 | 0.78% | 46,635 | -399 | -0.85% | 2024-12-31 |
| Monimus Capital Management, Lp | $542.00 | 0.7% | 42,067 | +42,067 | New | 2024-12-31 |
| Northern Trust Corp | $369.00 | 0.48% | 28,649 | -1,175 | -3.94% | 2024-12-31 |